



"Computational approaches in drug discovery: expectations and reality."

Stefano Moro

Molecular Modeling Section (MMS) Department of Pharmaceutical and Pharmacological Sciences

University of Padova

©2012





Vigo... nice memories:



2007

2010



... just to summarize the aim of our short course:


Farmaco Progettazione (drug) (design)

Informatica (informatics)

Why informatics can bridged drug-design?




I would like to start with a very pragmatic consideration:







TIME is the worse enemy in drug discovery...




Bringing a new drug to market can take 8-14 years and costs between \$400 and \$900 million






One of the possible strategy is the analysis of all failures:

B.Abrahamsson et al., in Drug Bioavailability, H.van der Waterbeemd Ed., Vol 18, Wiley-VCH, p495 (2002)





How we can reduce the unfavorable ratio xxx.000 to 1?



The worthwhile "pharma" goal (dream):

From Lead to Drug in Five Years

3st International Drug Discovery and Development Summit – December 2-5, 2008, Honolulu, Hi, USA

Priorities:


Lead selection using virtual screening;

In vitro screening for drug toxicity;


Solubility and bioavailability;

Animal models: accelerating discovery;

Accelerating clinical studies.



Informatics as synonymous of speed?





Informatics can help us to solve simple procedures in interactive way:

The calculation of a molecular weight is trivial, but the calculations of 4,5 millions of MW is not!

or solve extremely complex procedures:

Such as the calculation of symmetries and energies of molecular orbitals of a chemical structure or ligand-receptor binding energy (ΔG_{bind} , kcal x mol)!



Some costs details:

Experiment Typical Cost per Compound (€)


Computer modeling	7
Biochemical assay	270 Lead
Cell culture assay	2.700
Rat acute toxicity	8.100
Protein crystal structure	68.000
Animal efficacy trial	200.000
Rat 2-year chronic oral toxicity	550.000
Human clinical trial	3.500.000
Protein crystal structure Animal efficacy trial Rat 2-year chronic oral toxicity	200.000 550.000






Informatics is the basic science of any virtualization process:

From an informatics point of view, any computool is a *virtualization process*: the creation of a virtual version of the real process.






The *accuracy* of this virtualization process is crucial:






But what we need to virtualize in drug discovery process?





Flowcharts in Drug Discovery:





A easy way to define a screening process:

Biological Space

Profiling

Chemical Space


P	TargetA	TargetB	TargetC	TargetD	TargetN
Comp.1	K ₁ (A)	K ₁ (B)	K ₁ (C)	K ₁ (D)	K ₁ (N)
Comp.2	K ₂ (A)	K ₂ (B)	K ₂ (C)	K ₂ (D)	K ₂ (N)
Comp.3	K ₃ (A)	K ₃ (B)	K ₃ (C)	K ₃ (D)	K ₃ (N)
Comp.4	K ₄ (A)	K ₄ (B)	K ₄ (C)	K ₄ (D)	K ₄ (N)
Comp.n	K _n (A)	K _n (B)	K _n (C)	K _n (D)	K _n (N)

Screeninghemical Proteomics



What hit is...


HIT: a compound that acts on an assay system.





the "hit-to-lead paradigm": clear the xxx.000:1 ratio?







•>1,000,000

• 1,000,000

• 1,000

· 100

• Initial HTS campaign

• Quality control

• Primary hit selection

Hit validation

Bleicher et al. (2003) Nat. Rev. Drug Discov., 2, 369





Hit definition ...

hits

- active in assay
- defined and confirmed structures
- drug-like potential

HTS hits from this database typically show micromolar activity with a median "pPotency" of 6. The median molecular mass and lipophilicity (logP) was 359 Da and 3.8, respectively.





What about costs?

Experiment Typical Cost per Compound (€)

Computer modeling 7

Biochemical assay 270

Cell culture assay 2.700

Rat acute toxicity 8.100

Protein crystal structure 68.000

Animal efficacy trial 200.000

Rat 2-year chronic oral toxicity 550.000

Human clinical trial 3.500.000

... do you understand how crucial could be the prediction of possible new hits?





Hit to lead ...

leads

- potency established
- selectivity/specificity
- Mechanism of action (MOA) established
- in vivo efficacy
- ADME/Tox
- pharmaceutically acceptable





Well... now it's trivial

Experiment Typical Cost per Compound (€)

Computer modeling 7
Biochemical assay 270
Cell culture assay 2.700
Rat acute toxicity 8.100

Protein crystal structure 68.000

Animal efficacy trial 200.000

Rat 2-year chronic oral toxicity 550.000

Human clinical trial 3.500.000

... do you understand how magic could be the prediction of possible new leads?





We surely need informatics but:





xxx.000 to 1?

Is this ratio really acceptable for a pharma company?





We surely need informatics but:


LIGAND KNOWLEDGE


Known Ligands Pharmacophores Ligand Similarity QSAR Structure-Based Drug Design Ligand-Contact Analysis Bound-Ligand Morphing

Unknown Ligands Combinatorial Chemistry HTS Library Design De Novo Design Virtual Ligand Screening Virtual Target Screening

Unknown Target Structure Known Target Structure TARGET KNOWLEDGE











Before starting: lesson 0





We do NEVER forget:



This is a chemical

This is one of its possible chemical representations



... follow me in this logic comparison:

Real world

Virtual world

Chemical Compound (CC)

Chemical Structure (CS)

Chemical Properties (CP)

Numerical representazions of CS

Molecular Descriptors (MD)



With how many chemical representations we can deal?

C9H8O4

...again the salicylic acid?



The crucial informatics differences:

C9H8O4

... this is a simple *string* (sequence) of alphanumeric characters and it is very easy to manage... informatically!!!



Just a simple example: are these two representations identical?


C9H8O4

C9H8O4

Time of answer (sec):



Be careful to the chemical slang...







Remember, all of these are not identical... informatically specking!




Here is the informatics anatomy of this representation:








Now, this is perfect understandable!




MOE2007		odi atomi Numero di lega	ami tipo di atomo	
21 21		valler o ar legi		
1.1522	0.5113	-0.0537 C		
0.2183	1.2057	-0.8346 C		
0.5665	2.3445	-1.5679 O	0	
-1.0985	0.7524	-0.9667 C		
		е: 1.5911 н	· · · · · · · · · · · · · · · · · · ·	
-1.5038	-0.3936	-0.2868 C		
-2.5276	-0.7473	-0.3775 н		
-0 x 5938	-1.0370	0.5 2 9 C		
-0.9101	-1.9816	1.0411 H		
0.7269	-0.6400	0.6244 C		
1.4145	-1.2086	1.2469 Н		
0.5056	3.5095	0.8113 C	igii, Lead Mead Lead	
0.9559	4.6611	-1.6596 C		
0.9409	5.5777	-1.0629 Н		
0.2773	4.7842	-2.5073 H		
1.9783	4.4900	-2.0055 H		•
0.1372	3.6103	0.3517 0		0
2.5419	0.9700	0.0441 C		
3.0443	1.9108	-0.5504 O		•
3.2755	0.2254	0.8972 0		
4.1677	0.6310	0.8800 н		7
1 10 2	James T.	<u> </u>	Il primo legame è tra	
1 2 1 1 18 1	1.	No. of the same	l'atomo 1 e l'atomo 10 ed è	
1 18 1	4		The Control of the Co	
20 21 1	A. A.	J. Brown	di ordine 2 (doppio	
20 21 1 M END	Jane B		legame).	T
M END		70 No. 10		






Are we fully satisfied?





What we are really missing...





... the illusion of time!








Another important difference!

informatics



1 byte = 8 bit (1 bit = 0 o 1, true o false)





Combining business with pleasure?


C9H8O4

SMILES (Simplified Molecular Input Line Entry Specification)

Some SMILES rules:

CCCCCC1

metano etano propano H 2-metil-propano cicloesano



C=C

C=CC

C/C=C/C

C/C=C\C

C#C


etilene

propene

trans (E)-2-butene

cis (Z)-2-butene

etino (acetilene)



$$H$$
 H
 CH_3


H = H

c1cccc1 benzene

c1cccc1C toluene

c1ccc(N)cc1C 4-metil-anilina

c12c(cccc1)cccc2 naftalene



CCO

etanolo

etanale

acetone

acido acetico

reassuming:

C9H8O4


OC(=O)c1ccccc1(OC(=O)C)

Three faces of the same medal!!!




Searching in a database is now very easy!

Query



OC(=0)c1cccc1(OC(=0)C)





- 10 AME 21				
	F.BRUTA	mol	SMILES	
1	C7H6O2	O.	OC(=0)c1ccccc1	d.
2	С7Н6ОЗ	5	OC(=0)c1ccccc1(0)	
3	С9Н8О4	<u>}.</u>	OC(=0)c1ccccc1(OC(=0)C)	








MMsINC web-platform:




BESISTIAN (B) Molecular Modeling Section




| MMsINC_Search | MMsINC_Help | MMsINC_Roadmap | MMsINC_Credits | Feedback

MMsINC Search: OStructure Search OSimilarity to PDB ligands OAndhira

Structure Search





Note: MMsINC is offered to the fublic as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (MMsINC). We ask that users who download significant portions of the database cite the MMsINC paper in any resulting publications.

Copyright 2008, Molecular Modeling Section Lab and CRS4 Bioinformatics Lab. Report any bug to G. Frau or J. Masciocchi, or send your comments to S. Moro





Molecular Modeling Section



| MMsINC_Search | MMsINC_Help | MMsINC_Roadmap | MMsINC_Credits | Feedback |

Arzanol MMsInc code: MMs03967057

Type: Neutral Formula: C22H26O7

SMILES: O1C(=O)C(Cc2c(O)c(C(=O)C)c(O)c(CC=C(C)C)c2O)=C(O)C(C)=C1CC InChI: InChI=1/C22H26O7/c1-6-16-11(4)18(24)15(22(28)29-16)9-14-19(2 5)13(8-7-10(2)3)20(26)17(12(5)23)21(14)27/h7,24-27H,6,8-9H2,

1-5H3

Sdf File: MMs03967057.sdf

Similarity to PDB ligands





Mv NCBI [Sign In] [Register]

Search PubChem Compound v for "InChl=1/C22H26O7/c1-6-16-11(4)18(24)15(22(28)2 Go Clear Save Search Limits Preview/Index History Clipboard Details

Quoted phrase not found. See Details. No items found.

PubChem Help | Entrez Help | Write to the Help Desk

PubChem | Compound | Substance | BioAssay Chemical Structure Search | BioAssay Services | FTP Site | Deposit Data

NCBI NLM | NIH | HHS | Privacy Statement | Freedom of Information Act | Disclaimer



Ions/Tautometers related molecules: no related molecules available.





Molecular Modeling Section



| MMsINC_Search | MMsINC_Help | MMsINC_Roadmap | MMsINC_Credits | Feedback |

Arzanol MMsInc code: MMs03967057

Type: Neutral Formula: C₂₂H₂₆O₇


SMILES: O1C(=O)C(Cc2c(O)c(C(=O)C)c(O)c(CC=C(C)C)c2O)=C(O)C(C)=C1CC **InChI:** InChI=1/C22H26O7/c1-6-16-11(4)18(24)15(22(28)29-16)9-14-19(2

5)13(8-7-10(2)3)20(26)17(12(5)23)21(14)27/h7,24-27H,6,8-9H2,


1-5H3

Sdf File: MMs03967057.sdf





download 2D Mol File



download 3D Mol File

Potential Energy (e) Epot(MMFF94)=107.71 kcal/mol



Bloinformatics Lab



UNIVERSITA MODE Cular Modeling Section

A MEMBER OF THE PDB An Information Portal to Biological Macromolecular Structures As of Tuesday Jun 03, 2008 🔕 there are 51155 Structures 🔞 | PDB Statistics 🔞 CONTACT US | HELP | PRINT PAGE PDB ID or keyword
 Author Home Search Structure Are you missing data updates? The PDB archive has moved to ftp://ftp.wwpdb.org. For more information click here. Help Structure Summary Biology & Chemistry Materials & Methods Sequence Details Geometry ■ 1GCZ Download Files Images and Visualization 1gcz 🔃 🗎 🕝 FASTA Sequence DOI 10.2210/pdb1gcz/pdb << Biological Molecule >> Download Original Files Display Files Red - Derived Information Display Molecule Title MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) COMPLEXED WITH INHIBITOR. **■ Structural Reports** ■ External Links Authors Katayama, N., Kurihara, H. **▶** Structure Analysis ▶ Help Orita, M., Yamamoto, S., Katayama, N., Aoki, M., Takayama, K., Yamagiwa, Y., Seki, N., Suzuki, H., Kurihara, H., Sakashita, H., Takeuchi, M., Fujita, S., Yamada, T., Tanaka, A. (2001) Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography. *J.Med.Chem.* 44: 540-547 Quick Tips: ★ X [Abstract] When exploring a structure, select Structure Analysis and History Deposition 2000-08-24 Release 2001-02-21 then Geometry from the left Display Options @ menu to view a KING. Experimental Ramachandran Plot. Type X-RAY DIFFRACTION Data 1 [EDS] Method Jmol







| MMsINC_Search | MMsINC_Help | MMsINC_Roadmap | MMsINC_Credits | Feedback |

Query Type: Search using: Identical structure Gentical structure search tenimoto 0.0.85 Similarly search tenimoto 0.0.95 Molecular Descriptors: # Physical Properties Molecular Weight (MW) from to logs from to logs from Slopp from Reactive groups Reactive groups **Example 1.5 **Example 1.	Structure Search	
Query Type: Search using: Identical structure		Search Reset Save Query
Search using: Identical structure v Iden		Query Type:
Query Data: Substructure search Similarity search, tanimoto>0.95 Similarity search, tanimoto>0.95 Molecular Scissoring		
Input: ● SM Similarity search, tanimoto>0.9 Similarity search, tanimoto>0.9 Molecular Formula Molecular Scissoring CCc2oc(=0)c(Cc1c(0)c(CC=C(C)C)c(0)c(C(C)=0)c10)c(0)c2C Molecular Descriptors: Physical Properties Molecular Weight (MW) from to logS from SlogP from to logS from SlogP from to logS from logS from to logS from logS from to logS from	он он	Substructure search
Molecular Sassoning CCc2oc(=0)c(Cc1c(0)c(CC-C(c)C)c(0)c(C)c(0)c(0)c2C Molecular Descriptors:		Similarity search, tanimoto>0.9 Input: SMI Similarity search, tanimoto>0.95 Molecular Formula
Molecular Descriptors: ⊞ Physical Properties Molecular Weight (MW) from to logS from to SlogP from to Reactive groups + Topological Properties + Surface and Volume Properties + Pharmacophoric Properties + Pharmacophoric Properties	OH OH	Molecular Scissoring
Physical Properties Molecular Weight (MW) from to logS from to SlogP from to Reactive groups Select a value ▼ + Topological Properties + Surface and Volume Properties + Pharmacophoric Properties		CCc2oc(=0)c(Cc1c(0)c(CC=C(C)C)c(0)c(C(C)=0)c10)c(0)c2C
Molecular Weight (MW) from to logS from to SlogP from to Reactive groups Select a value ▼ + Topological Properties + Surface and Volume Properties + Pharmacophoric Properties	x	Molecular Descriptors:
logS from to SlogP from to Reactive groups Select a value ▼ + Topological Properties + Surface and Volume Properties + Pharmacophoric Properties		
SlogP from Reactive groups + Topological Properties + Surface and Volume Properties + Pharmacophoric Properties	Create SMILES Clear Editor	
Reactive groups + Topological Properties + Surface and Volume Properties + Pharmacophoric Properties	AL AS NEW YORK	-
+ Surface and Volume Properties + Pharmacophoric Properties		_
+ Pharmacophoric Properties		+ Topological Properties
+ Drug- and Lead-like Properties	All	+ Pharmacophoric Properties
		+ Drug- and Lead-like Properties
		Search Reset Save Query




Molecular Modeling Section

| MMsINC_Search | MMsINC_Help | MMsINC_Roadmap | MMsINC_Credits | Feedback |

Molecule found with a Tanimoto Coefficent superior or equal to 0.85

Items found 1 - 20 of 200





Molecular Modeling Section



| MMsINC Search | MMsINC Help | MMsINC Roadmap | MMsINC Credits | Feedback |

MDPI-ZINC03843495

Type: Neutral Formula: C19H20O6

SMILES: Oc1c(C)c(O)c(cc1Cc1cc(C(=O)C)c(O)c(C)c1O)C(=O)C

InChI: InChI=1/C19H20O6/c1-8-16(22)12(6-14(10(3)20)18(8)24)5-13-7-1

5(11(4)21)19(25)9(2)17(13)23/h6-7,22-25H,5H2,1-4H3

Sdf File: MMs02176936.sdf





PubChem Compound

PubMed | Entrez | Structure | PubChem | Help

MMsInc code: MMs02176936

ZINC03843495 - Compound Summary (CID: 2748081)

Table of Contents

PubChem » Compound Summary

- Synonyms
- Properties
- Descriptors
- Compound Info
- Substance Info
 - Substance Category
- Exports




ZINC03843495

Properties Computed from Structure: 2

Molecular Weight	344.3585 [g/mol]
Molecular Formula	C ₁₉ H ₂₀ O ₆
XLogP	1.5
H-Bond Donor	4






Compound 10	2740001	(3)
Molecular Weight	344.3585 [g/mol]	2
Molecular Formula	C ₁₉ H ₂₀ O ₆	?
XLogP	1.5	?
H-Bond Donor	4	?
H-Bond Acceptor	6	2








| MMsINC_Search | MMsINC_Help | MMsINC_Roadmap | MMsINC_Credits | Feedback |





Molecule result, page: 1 Items found 1 - 20 of 75






UNIVERSITY (II) Molecular Modeling Section



| MMsINC_Search | MMsINC_Help | MMsINC_Roadmap | MMsINC_Credits | Feedback |

Molecule result, page: 1

Items found 3



Copyright 2008, Molecular Modeling Section Lab and CRS4 Bioinformatics Lab. Report any bug to G. Frau or J. Masciocchi, or send your comments to S. Moro